Molnlycke Health Care AB
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Molnlycke Health Care AB sits in the top decile of US sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count).
Molnlycke Health Care AB: 20 sponsored US clinical trials, 2 recruiting.
Molnlycke Health Care AB sponsors 20 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 15 completed. 4 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Wounds, with 2 trials.
Top-decile sponsor footprint
Molnlycke Health Care AB ranks in the top decile of sponsors by registered trial count (#743 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
15 of 16 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
20 total, page 1 of 1
A Clinical Investigation to Follow the Progress of Exuding Chronic Venous Leg Ulcers Using a Non-Bordered Foam Dressing
NCT05608317
A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing.
NCT05588583
Interventional Study Exploring the Occurrence of Surgical Site Infections.
NCT06661473
Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns
NCT04839523
An Open, Non-comparative, Multicenter Investigation to Evaluate the Safety and Performance of Exufiber Ag+, a Gelling Fiber Silver Dressing, When Used in Medium to High Exuding Chronic Wounds
NCT05494450
Evaluation of the Residual Antimicrobial Efficacy of One Test Material Based on a Modification of ASTM E1115-11 Test Method
NCT04654182
Evaluation of Chlorhexidine Gluconate Concentration on Skin of Human Subjects Following Multiple Application Times
NCT04235985
Clinical Study to Compare 3 Multi-Layered Foam Dressings for the Management of Chronic Wounds
NCT03662997
Durability of Double-gloving With Biogel® Surgical Gloves When Used by Clinicians/Surgeons
NCT03344354
Evaluation of Exufiber Ag+ and Other Gelling Fibre Dressings
NCT03249909
Self-adherent Absorbent Silver Dressing in Adults After Hip or Knee Arthroplasty
NCT03016078
Pressure Injury Prevention in the ICU With Multi-Layer Foam Dressings
NCT02962882
A Soft Silicone Wound Contact Layer Containing Silver in the Treatment of Skin Grafts in Surgical Burn Patients.
NCT02210208
An Open Single-centre Investigation Evaluating Efficacy in Second Degree Partial Thickness Burns Using a Silicone Contact Layer Containing Silver.
NCT01734317
An Investigation to Evaluate a New Donor Site Dressing in Surgical Burn Patients
NCT01670201
A Clinical Investigation to Evaluate Efficacy of Mepitel Ag in Partial Thickness Second Degree Burns
NCT01636362
Clinical Utility of a New Silver Gel for Use on Chronic Wounds
NCT01442103
Open, Prosp, Rand. Invest. Evaluating Pain With Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts
NCT01365273
Open Multi-centre Investigation to Evaluate Signs and Symptoms of Local Inflammation/Infection on Chronic Ulcers and Partial Thickness Burns When Using Mepilex Border Ag as an Anti-microbial Wound Dressing
NCT01214811
Evaluating the Cost-effectiveness, Efficacy, Safety and Tolerance of Mepilex® Ag Versus Silvadene®
NCT00742183
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 3 |
Therapeutic Areas
Where Molnlycke Health Care AB enrollment is open (later-stage tilt)
2 recruiting of 20 indexed (10% open); 15 completed (75%).
Phase mix: 4 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Wounds (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Molnlycke Health Care AB: open-pipeline peers nationwide
Peers matched on 20 registered trials and 10% open enrollment, not the therapeutic-area sidebar.
Molnlycke Health Care AB sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 20 trials (± recruiting share)
- 59th Medical Wing · 20 trials · 15% recruiting
- Abiomed · 20 trials · 10% recruiting
- Agency for Healthcare Research and Quality (AHRQ) · 20 trials · 0% recruiting
- Alliance Foundation Trials · 20 trials · 15% recruiting
Sponsors near 10% open enrollment (± trial volume)
- Aimmune Therapeutics · 10% recruiting · 10 trials
- Altria Client Services · 10% recruiting · 10 trials
- Alzheimer's Disease Cooperative Study (ADCS) · 10% recruiting · 10 trials
- Ascension Health · 10% recruiting · 10 trials
Related
What to do with this Molnlycke Health Care AB page
20 registered trials is a research-attention snapshot, not an endorsement of Molnlycke Health Care AB or any single study.
- 2 of Molnlycke Health Care AB's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Wounds is the condition Molnlycke Health Care AB studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Wounds trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Molnlycke Health Care AB pipeline card: 20 registered trials from official public datasets.Report a data error.